Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer

Drugs of Today

Volumn 46, Issue 9, 2010, Pages 641-653

  Mani, Sridhar ^a   Swami, U ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; CAPECITABINE; CARBAMAZEPINE; CARBOPLATIN; CISPLATIN; DIAZEPAM; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERIBULIN; GEMCITABINE; HALICHONDRIN B; MACROCYCLIC COMPOUND; MIDAZOLAM; NAVELBINE; PACLITAXEL; TAMOXIFEN; TERFENADINE; TRASTUZUMAB; VINBLASTINE;

ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CONTINUOUS INFUSION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY REACTION; HYPOGLYCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; IN VITRO STUDY; IN VIVO STUDY; INFECTION; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROMETAPHASE; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR REGRESSION; URINARY EXCRETION; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; ETHERS, CYCLIC; FEMALE; FURANS; HUMANS; KETONES; MESYLATES;

EID: 79955887466     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.9.1519020     Document Type: Review

References (45)

1. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, Z., Thun, M.J. Cancer Statistics, 2009. CA Cancer J Clin 2009, 59(4): 225-49.
2. Arriagada, R., Spielmann, M., Koscielny, S. et al. Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen. Ann Oncol 2002, 13(9): 1378-86.
3. Hirata, Y., Uemura, D. Halichondrins: Antitumor polyether macrolides from a marine sponge. Pure Appl Chem 1986, 58(5): 701-10. (Pubitemid 16557441)
4. Pettit, G.R., Herald, C.L., Boyd, M.R. et al. Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp. J Med Chem 1991, 34(11): 3339-40.
5. Bai, R.L., Pauli, K.D., Herald, C.L., Malspeis, L., Pettit, G.R., Hamel, E. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 1991, 266(24): 15882-9. (Pubitemid 21907740)
6. Aicher, T.D., Buszek, K.R., Fang, F.G. et al. Total synthesis of halichondrin B and norhalichondrin B. J Am Chem Soc 1992, 114(8): 3162-4.
7. Yu, M.J., Kishi, Y., Littlefield, B.A. Discovery of E7389, a fully synthetic macrocyclic ketone analogue of halichondrin B. In: Anticancer Agents from Natural Products. Cragg, G.M., Kingston, D.G.I., Newman, D.J. (Eds.). Taylor & Francis Group (CRC Press): Boca Raton, 2005, 241-65.
8. Product information, Eisai Inc.
9. "Drugs.com, Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application". http://www.drugs.com/nda/e7389-080201.html. Retrieved on 2008-02-06.
10. Smith, J.A., Wilson, L., Azarenko, O., Zhu, X., Lewis, B.M., Littlefield, B.A., Jordan, M.A. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 2010, 49(6): 1331-7.
11. Dabydeen D.A., Burnett J.C., Bai R. et al. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol 2006, 70(6): 1866-75.
12. Towle, M.J., Salvato, K.A., Budrow, J., et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001, 61(3): 1013-21.
13. Budman, D.R., Calabro, A., Littlefield, B.A. Synergestic combinations of E7389 (halichondrin B analogue) with conventional agents: In vitro median effect analysis in cell lines with potential clinical implications. 27th Annu San Antonio Breast Cancer Symp (Dec 8-11, San Antonio) 2004, Abst 6055.
14. Kuznetsov, G., Tendyke, K., Yu, M., Littlefield, B. Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer ceils in vitro. Proc Am Assoc Cancer Res (AACR) 2007, 48: Abst C58.
15. Towle, M.J., Agoulnik, S., Kuznetsov, G. et al. In vivo efficacy of E7389, a synthetic analogue of the marine sponge atitubulin agent halichondrin B, against human tumor xenografts under monotherapy and combination therapy conditions. Proc Am Assoc Cancer Res (AACR) 2003, 44(2nd Ed.): Abst 2749.
16. Alley, M.C., Smith, A.C., Donohue, S.J., Schweikart, K.M., Newman, D.J., Tomaszewski, J.E. Comparison of the relative efficacies and toxicities of halichondrin B analogues. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-18, Philadelphia) 2005, Abst C230.
17. Jordan, M.A., Kamath, K., Manna, T. et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005, 4(7): 1086-95. (Pubitemid 41079102)
18. Okouneva, T., Wilson, L., Littlefield, B.A., Jordan, M.A. E7389 and ER-076349, synthetic halichondrin B analogs, suppress centromere dynamics in concert with mitotic block. Proc Am Assoc Cancer Res (AACR) 2001, 45: Abst 5436.
19. Kamath, K., Okouneva, T., Miller, H. et al. E7389, a synthetic analog of halichondrin B, suppresses microtubule dynamics in living MCF7 cells by a novel mechanism. Proc Am Assoc Cancer Res (AACR) 2003, 44(2nd Ed.): Abst LB-43.
20. Kuznetsov, G., Towle, M.J., Cheng, H. et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analogue E7389. Cancer Res 2004, 64(16): 5760-6. (Pubitemid 39095575)
21. Agoulnik, S., Kuznetsov, G., Tendyke, K. et al. Sensitivity to halichondrin analog E7389 and hemiasterlin analog E7974 correlates with βIII tubulin isotype expression in human breast cancer cell lines. J Clin Oncol [41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, 23(16, Suppl.): Abst 2012.
22. Seve, P., Dumontet C. Is class III β-tubulin a predictive factor in patients receiving tubulin-bindlng agents? Lancet Oncol 2008, 9(2): 168-75.
23. Synold, T.W., Morgan, R.J., Newman, E.M. et al. A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial. J Clin Oncol [41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, 23(16, Suppl.): Abst 3036.
24. Synold, T.W., Lawrence, J., Xi, B., Colevas, A.D., Lewis, M.D., Doroshow, J.H. Human pharmacokinetics of E7389 (halichondrin B analog), a novel anti-microtubule agent undergoing phase I investigation in the California Cancer Consortium (CCC). Proc Am Soc Clin Oncol (ASCO) 2003, 22: Abst 575.
25. Goel, S., Mita, A.C., Mita, M. et al. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 2009, 15(12): 4207-12.
26. Tan, A.R., Rubin, E.H., Walton, D.C. et al. Phase I study of eribulin mesylate (E7389) administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 2009, 15(12): 4213-9.
27. Minami, H., Mukohara, T., Nagai, S., Mukai, H., Namiki, M. A phase I study of eribulin mesylate (E7389) in patients with refractory cancers. Eur J Cancer Suppl [20th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (Oct 21-24, Geneva) 2008] 2008, 6(12): Abst 446.
28. Swami, U., Petrylak, D.P., Raftopoulos, H. et al. Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors. J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 2589.
29. Witteveen, P., Marchetti, S., Mergui-Roelvink, M., et al. Eribulin mesylate pharmacokinetics in patients with hepatic impairment. J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 2582.
30. Jansen, M., Vernaz-Gris, M., DesJardins, C. et al. Population pharmacokinetics (PPK) of eribulin mesylate in patients with locally advanced or metastatic breast cancer (MBC). J Clin Oncol [45th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 15(Suppl.): Abst 2524.
31. Zheng, W., Seletsky, B.M., Palme, M.H. et al. Structure-activity relationships of synthetic halichondrin B analog E7389: In vitro susceptibility to PgP-mediated drug efflux. Proc Am Assoc Cancer Res (AACR) [94th Annu Meet Am Assoc Cancer Res (AACR) (July 10-14, Washington, D.C.) 2003] 2003, 44(2nd Ed.): Abst 2751.
32. Zhang, Z.Y., King, B.M., Pelletier, R.D. Wong, Y.N. Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother Pharmacol (2008) 62(4): 707-16.
33. Simon, R., Freidlin, B., Rubinstein, L., Arbuck, S.G., Collins, J., Christian, M.C. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997, 89(15): 1138-47. (Pubitemid 27337928)
34. Synold, T.W., Tsao-Wei, D.D., Quinn, D.I. et al. Phase I and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts) with renal dysfunction (RD) and advanced urothelial cancer (UC): A California Cancer Consortium Trial. J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 2527.
35. Vahdat, L.T., Twelves, C., Allison, M.A. et al. Phase II study of eribulin mesylate (E7389) in patients (PTS) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracycline, taxane, and capecitabine therapy. J Clin Oncol [44th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2008] 2008, 26(15, Suppl.): Abst 1084.
36. Vahdat, L.T., Pruitt, B., Fabian, C.J. et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009, 27(18): 2954-61.
37. Therasse, P., Arbuck, S.G., Eisenhauer, E.A. et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3): 205-16.
38. Gupta, D., Mani, S. The efficacy and safety of ixabepilone monotherapy in the treatment of breast and gynecologic malignancies. Expert Opin Drug Saf 2009, 8(1): 81-8.
39. A study comparing eribulin mesylate and ixabepilone in causing or exacerbating neuropathy in patients with advanced breast cancer (NCT00879086). ClinicalTrials.gov Web site, September 6, 2010.
40. Cortes, J.A, Campone, M., Twelves, C. et al. Eribulin mesylate (E7389) in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane: Phase II neuropathy data. Ann Oncol [33rd Eur Soc Med Oncol (ESMO) Congr (Sept 12-16, Stockholm) 2008] 2008, 19(Suppl. 8): Abst 156P.
41. Iwata, H., Aogi, K., Masuda, N. et al. Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer. J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 1081.
42. Twelves, C., Cortes, J., Vahdat, L.T., Wanders, J., Akerele, C., Kaufman, P.A. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer 2010, 10(2): 160-3.
43. Twelves, C., Loesch, D., Blum, J.L. et al. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst CRA1004.
44. E7389 versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer (NCT00388726). ClinicalTrials.gov Web site, September 6, 2010.
45. Phase III study results showed Eisai's eribulin mesylate significantly improved overall survival in patients with locally recurrent or metastatic breast cancer: Global EMBRACE study compared eribulin to treatment of physician's choice. Eisai Co., Ltd. Press Release, June 6, 2010.